BrainStorm Reports Q1 2026 Financial Results and ALS Study Update
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 15 2026
0mins
Source: PRnewswire
- Financial Overview: As of March 31, 2026, BrainStorm reported total assets of $755,000, down from $1,022,000 as of December 31, 2025, indicating ongoing financial pressure that may impact future funding capabilities.
- Increased R&D Spending: The company incurred $762,000 in R&D expenses for Q1 2026, a significant decrease from $1,304,000 in the same period last year, reflecting a strategic shift in resource allocation aimed at optimizing the development of NurOwn.
- Net Loss Situation: BrainStorm's net loss for Q1 2026 was $2,127,000, an improvement from $2,864,000 in Q1 2025, suggesting progress in cost control despite ongoing challenges.
- ALS Research Progress: The company is actively advancing the Phase 3 ENDURANCE study of NurOwn, targeting early-stage ALS patients, which, if successful, could provide new treatment options and underscores BrainStorm's commitment to the ALS community and the market potential involved.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
